Kim Nguyen Chi, MD, FRCPC, discusses correlative analyses of prognostic subgroups in the phase 2 PR21 study in PSMA-positive mCRPC.
Kim Nguyen Chi, MD, FRCPC
Advertisement
Kim Nguyen Chi, MD, FRCPC, is a medical oncologist at Vancouver Cancer Centre and Vancouver Prostate Centre, chief medical officer and Shrum Chair in Prostate Cancer Research for BC Cancer – Vancouver, and a professor in the faculty of Health Sciences at Simon Fraser University.
Articles by Kim Nguyen Chi, MD, FRCPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
5